Module

Managing Dyslipidemia in HIV-Infected Patients on Therapy: Switch Antiretroviral Agents or Add Lipid-Lowering Agents?

Source: Managing Dyslipidemia in HIV-Infected Patients on Therapy: Switch Antiretrovirals or Add Lipid-Lowering Agents?

Managing Dyslipidemia in HIV-Infected Patients on Therapy: Switch Antiretroviral Agents or Add Lipid-Lowering Agents?


Faculty:

Marshall J. Glesby, MD, PhDJames H. Stein, MD
  • Marshall J. Glesby, MD, PhD
  • James H. Stein, MD

CME CREDIT INFORMATION

Release Date: 09/09/08

Expiration Date: 09/08/09


Physicians: maximum of 1.75 AMA PRA Category 1 Credits

Registered Nurses: 1.7 Nursing CE credits

Status: Please log in to view status


Begin the Module

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recall the effects that different antiretroviral classes, and specific drugs within classes, have on lipids
  • Discuss the results of recent trials attempting to improve lipid abnormalities in HIV-infected patients receiving antiretroviral agents
  • Describe the benefits associated with various lipid-lowering therapies in HIV-infected patients receiving antiretroviral agents
  • Summarize strategies to both prevent and control cardiovascular risk in HIV-infected patients on antiretroviral therapy

Topics covered include:

  • Introduction
  • Multifactorial Etiology of Dyslipidemia
  • Effects of Antiretroviral Therapy on Lipids
  • Switching Antiretroviral Therapy
  • The Case for Adding Lipid-Lowering Therapy
  • Overview of Lipid-Lowering Agents
  • Lipid-Lowering Therapy in Clinical Practice
  • Managing HIV-Infected Patients With Cardiovascular Risk
  • Discussion of Cases
  • Questions and Answers


Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.